Back to catalog

Product details

Tesmorelin

$48.99$69.9910mg · per unit

Save $21.00 per unit with current offers

Explore Tesmorelin amounts, pricing, and product information.

Front view of Tesmorelin
Tesmorelin10mgRESEARCH USE ONLY
-30%

Select your product

Amount
Bundle and save

Bundle savings apply after the sale price. Same product and amount: 2–3 bottles save 3% extra, 4–10 save 6%, and 11+ save 30%.

10mg · 1 unit · Total

$48.99$69.99

$48.99 per unit

Save $21.00 total

WINTER30 −30%

Save your selection in the cart. Ordering is not open. Contact us for availability.

For laboratory research only. Not for human or veterinary use. Research-use policy.

Know your compound

Compound information

Tesmorelin

Tesamorelin and TH9507 are reviewed research names associated with the catalog spelling Tesmorelin.

Identity references 1 source
Catalog identity
Tesmorelin
Intended use
Laboratory research
Research names
Tesamorelin · TH9507
Reference molecule
Tesamorelin
PubChem record
CID 16137828
Molecular formula
C221H366N72O67S
Molecular weight
5136 g/mol

Molecular data describe the reference compound in PubChem, not a laboratory analysis of this product or batch.

Primary literature

Verified research references

Primary-source bibliography for the named compound. These studies did not test this catalog item.

Randomized human research included

Tesamorelin1 verified reference

Identity note

Catalog productSlug preserves the existing "tesmorelin" spelling; study metadata uses "tesamorelin".

  1. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

    Falutz J · 2010 · J Clin Endocrinol Metab

    Study design
    Pooled randomized controlled trials
    Research context
    Human research
    Sample size
    806 participants or samples
    Study population
    Antiretroviral-treated people with HIV and excess abdominal fat
    Duration
    26-week randomized phase plus 26-week safety extension

    PMID: 20554713

    DOI: 10.1210/jc.2010-0490

Bibliographic references do not establish the identity, purity, safety, effectiveness, or suitability of this catalog item and are not use guidance. For legitimate laboratory and research use only; not for human or veterinary use.

Related catalog